Arzoxifene: the development and clinical outcome of an ideal SERM

Expert Opinion on Investigational Drugs
Pamela N Munster

Abstract

Hormone-sensitive tumours are among the most common cancers in women. Specific inhibition of the estrogen receptor by selective estrogen receptor downregulators or selective estrogen receptor modulators (SERMs) is effective for the treatment of breast and endometrial cancers and may be used for the prevention of breast cancer. Due to differential recruitment of co-activators and corepressors, SERMs are tissue specific and may have antiestrogenic effects in some tissues, with estrogen agonist activity in others. The ideal SERM would have antiestrogenic effects on the breast and endometrium, but pro-estrogenic effects on bone and lipids. The SERM, arzoxifene (LY-353381.HCl) meets all of these criteria. This review summarises the development, preclinical studies and the clinical outcome of arzoxifene and places it in context with other modalities in the treatment of hormone receptor-positive tumours.

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L J Vatten, S Kvinnsland
Jan 1, 1988·Oncology·A U BuzdarG Hortobagyi
Aug 1, 1983·Endocrinology·S M SchollM E Lippman
Jun 12, 1995·Annals of the New York Academy of Sciences·R Fuchs-YoungH U Bryant
Jan 2, 1993·Lancet·A KalacheS G Thompson
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B Fisher
Apr 1, 1997·The Journal of Steroid Biochemistry and Molecular Biology·J A DodgeH U Bryant
Feb 12, 1998·Proceedings of the National Academy of Sciences of the United States of America·T A GreseJ A Dodge
Mar 24, 1999·Journal of the National Cancer Institute·A H WuD O Stram
Jul 27, 1999·The Journal of Steroid Biochemistry and Molecular Biology·H U BryantM Sato
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BonneterreM von Euler
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzM von Euler
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P N MünsterC Hudis
Mar 30, 2002·Science·Yongfeng Shang, Myles Brown
Dec 10, 2002·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Yanfei L MaMasahiko Sato
Dec 31, 2002·JAMA : the Journal of the American Medical Association·Joan Stephenson
Feb 13, 2003·JAMA : the Journal of the American Medical Association·Joan Stephenson
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aman BuzdarClifford Hudis
Jun 26, 2003·JAMA : the Journal of the American Medical Association·Rowan T ChlebowskiUNKNOWN WHI Investigators
Jul 31, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M NabholtzB Thürlimann
Aug 9, 2003·The New England Journal of Medicine·JoAnn E MansonUNKNOWN Women's Health Initiative Investigators
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BaselgaL Petruzelka
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ParidaensUNKNOWN European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBB
Oct 15, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B ThürlimannUNKNOWN Arimidex Study Group
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study

❮ Previous
Next ❯

Citations

Sep 19, 2006·Chemical Research in Toxicology·Tamara S DowersJudy L Bolton
Feb 3, 2009·Menopause : the Journal of the North American Menopause Society·Hugh S Taylor
Oct 3, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P NevenJ VAN Ginderachter
Jan 1, 2014·The Journal of Steroid Biochemistry and Molecular Biology·Joann V Pinkerton, Semara Thomas
Nov 26, 2014·Menopause : the Journal of the North American Menopause Society·David F ArcherGinger D Constantine
Mar 29, 2014·The Journal of Steroid Biochemistry and Molecular Biology·Barry S Komm, Sebastian Mirkin
Dec 4, 2014·Maturitas·Sebastian Mirkin, James H Pickar
Nov 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vijayalaxmi DeshmaneAman U Buzdar
Jan 29, 2010·Menopause : the Journal of the North American Menopause Society·JoAnn V Pinkerton, Steven R Goldstein
Feb 19, 2008·Obstetrical & Gynecological Survey·Wendy ShellyRobert B Jaffe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.